Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light.

Autor: Zhang J; Department of Gastroenterology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Yangpu District, Shanghai, 200092, China., Wu K; Department of Gastroenterology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Yangpu District, Shanghai, 200092, China., Shi C; Department of Gastroenterology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Yangpu District, Shanghai, 200092, China. shicuicui@xinhuamed.com.cn., Li G; Department of Gastroenterology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Yangpu District, Shanghai, 200092, China. liguangming@xinhuamed.com.cn.
Jazyk: angličtina
Zdroj: Current treatment options in oncology [Curr Treat Options Oncol] 2022 Dec; Vol. 23 (12), pp. 1777-1792. Date of Electronic Publication: 2022 Oct 24.
DOI: 10.1007/s11864-022-01027-2
Abstrakt: Opinion Statement: Immunotherapy is revolutionizing tumor treatment by activating the immune response to tumors. Among them, immunotherapy represented by immune checkpoint inhibitors is considered to be a milestone in tumor treatment. It has revolutionized the management of advanced malignant tumors by activating T cells, promoting cytotoxic signaling pathways, and killing tumor cells, effectively improving the overall survival of patients. However, resistance to immunotherapy and immune-related adverse events remain challenges for immunotherapy. It has been demonstrated in previous studies that modulating intestinal microbiota can enhance immunotherapy response and reduce complications. Currently, the more mature method for microbiota regulation is fecal microbiota transplantation, which involves transfering a donor's microbiome to the recipient in the form of capsules or fecal microbiota suspension to restore the richness of the recipient's intestinal microbiota. In terms of cancer immunotherapy, fecal microbiota transplantation in patients who fail to respond to immune checkpoint inhibitors is expected to produce better prognosis for patients.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: